指南与共识肝病

代谢功能障碍相关脂肪性肝病与脂肪性肝炎的全球共识推荐

Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis.
指南 / 共识 · Gastroenterology · 2025-04-11

该共识基于2018年1月至2025年1月发表的61份MASLD/MASH指南等文件,经8个领域145个变量评估和四轮Delphi流程形成推荐;最终共识推荐以表格和算法汇总。

要点

  • 共检索到2018年至2025年1月发表的61份MASLD/MASH相关文件。
  • 采用8个领域145个变量评估,一致性低于50%的变量进入Delphi流程。
  • 四轮Delphi后全部声明获得超过90%的同意率。

核心结论

  • 该研究基于对最新MASLD/MASH指南的全面回顾和共识构建过程,提供了一套广泛的推荐。

研究设计与样本

  • 通过PubMed、Embase、Web of Science和学会网站检索2018年1月至2025年1月发表的MASLD和MASH指南、指导文件或类似出版物。
  • 每份入选文件按8个特定领域和145个变量进行评估,一致性低于50%的变量用于Delphi声明开发。
  • 声明接受阈值设为超多数67%,共进行四轮Delphi。

主要发现

  • 2018年至2025年1月共发表61份文件。
  • 第一轮生成46条声明,第二轮32条,第三轮16条,第四轮8条,其中100%的声明获得超过90%的同意率。
  • 所有最终共识推荐均汇总于表格和算法中。

关键数值与推荐

  • 一致性低于50%的变量用于Delphi声明开发。
  • 声明接受的超多数阈值为67%。
  • 第一轮46条声明,第二轮32条,第三轮16条,第四轮8条,100%的声明获得超过90%的同意率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are associated with adverse clinical outcomes, impaired health-related quality of life, and significant economic burden. The growing burden of MASLD and MASH has led to the publication of a large number of MASLD/MASH guidelines by national and international societies. However, important differences among the recommendations have created confusion, contributing to a low implementation rate and suboptimal management of MASLD and MASH. Creating a consensus recommendation has become more important since the approval of a selective agonist of thyroid hormone β receptor (resmetirom) for MASH treatment in the United States. We built a consensus among the most recently published recommendations for MASLD/MASH. METHODS: A comprehensive search for MASLD and MASH guidelines, guidance documents, or similar publications from January 2018 to January 2025 using PubMed, Embase, Web of Science, and society websites was conducted. Each selected document was assessed across 8 specific domains with 145 variables. Variables with <50% concordance were used for the Delphi statement development. A supermajority threshold of 67% was set for statement acceptance. RESULTS: There were 61 documents published from 2018 through January 2025. Four rounds of Delphi were conducted: 46 statements were generated for Round 1, 32 statements for Round 2, 16 statements for Round 3, and 8 statements for Round 4, whereby 100% of statements achieved a greater than 90% agreement. All final consensus recommendations were summarized in tables and algorithms. CONCLUSIONS: Our study provides an extensive set of recommendations generated based on a comprehensive review of the most recent MASLD/MASH guidelines and a consensus-building process.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Zelber-Sagi S, Lazarus JV, et al. Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Gastroenterology. 2025. PMID: 40222485. doi:10.1053/j.gastro.2025.02.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。